GlassScriptPhysician profile
David Joseph Wenzke
NPI 1275573354
$142,839.16
in general payments reported to CMS, 2019-2025
31 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $862 · 2021: $1,385 · 2022: $10K · 2023: $40K · 2024: $89K · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Travel and Lodging: $9,018 · Food and Beverage: $7,970 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,890.00 |
| Travel and Lodging | $9,017.65 |
| Food and Beverage | $7,970.04 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $86,425.36 | 2019-2024 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $27,964.81 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Phathom Pharmaceuticals, INC. | $9,186.80 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $8,474.07 | 2019-2022 | |
| Lilly USA, LLC | $7,115.55 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $960.82 | 2021-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.20 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $342.04 | 2019-2024 | |
| Celgene Corporation | $335.92 | 2019-2024 | Zeposia |
| Pfizer INC. | $324.53 | 2019-2023 | |
| Qol Medical, LLC | $236.29 | 2021-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $218.87 | 2020-2024 | Linzess |
| Genzyme Corporation | $110.25 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $96.99 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $96.27 | 2019-2023 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $80.24 | 2022-2024 | Renflexis |
| Ipsen Biopharmaceuticals, INC | $69.45 | 2024 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $51.49 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $28.01 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $26.18 | 2020-2023 | Ocaliva |
| Braintree Laboratories, INC. | $26.14 | 2022 | |
| Ardelyx, INC. | $18.83 | 2024 | Ibsrela |
| Shionogi INC | $17.88 | 2019 | |
| Celltrion USA INC. | $17.22 | 2024 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $16.97 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.48 | 2020 | |
| Novo Nordisk INC | $15.98 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.31 | 2023 | Cyltezo |
| Olympus America INC. | $14.34 | 2023 | Evis Exera III Video System Center |
| Evoke Pharma, INC. | $12.76 | 2021 | |
| Lucid Diagnostics INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wenzke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.